Page last updated: 2024-09-04

canertinib and Benign Neoplasms, Brain

canertinib has been researched along with Benign Neoplasms, Brain in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Appleman, VA; Charest, A; Jun, HJ; Sarkaria, JN; Varma, H; Yeo, AT; Zhang, P1
Al-Nedawi, K; Garnier, D; Guha, A; Lee, TH; Lee, WJ; Meehan, B; Montermini, L; Rak, J1

Other Studies

2 other study(ies) available for canertinib and Benign Neoplasms, Brain

ArticleYear
EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.
    Oncogene, 2021, Volume: 40, Issue:15

    Topics: Animals; Apoptosis; Brain Neoplasms; ErbB Receptors; Glioblastoma; HEK293 Cells; Heterografts; Humans; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, Platelet-Derived Growth Factor alpha

2021
Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.
    The Journal of biological chemistry, 2015, Oct-02, Volume: 290, Issue:40

    Topics: Animals; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Cetuximab; Culture Media, Conditioned; DNA; ErbB Receptors; Etoposide; Exosomes; Extracellular Vesicles; Glioma; Humans; Mice; Mice, SCID; Morpholines; Neoplasm Transplantation; Neoplasms; Phosphoproteins; Phosphorylation; Proteomics; Quinazolinones; Transfection

2015